Selank: What the Research Says
Regulatory notice: Selank is currently classified as an FDA Category 2 bulk drug substance. As of April 2026, licensed compounding pharmacies are not legally permitted to prepare or dispense it. PepScribe does not currently offer Selank and has no confirmed timeline for availability. This page is for educational purposes only and does not constitute medical advice or an offer to sell any product.
On February 27, 2026, the U.S. Department of Health and Human Services announced an intent to reclassify certain peptides, potentially including Selank. This announcement has not been formally published in the Federal Register and carries no legal effect until it is. Do not interpret this page as confirmation that Selank's legal status has changed or that PepScribe will offer it in the future.
What is Selank?
Selank is a synthetic 7-amino-acid peptide developed in the early 1990s by Seredenin, Kozlovskaya, and colleagues at the Institute of Molecular Genetics of the Russian Academy of Sciences. It's a modified analog of tuftsin, a naturally occurring tetrapeptide that your body produces from immunoglobulin G (IgG). The modification adds a D-amino acid and a Pro-Gly-Pro tail that significantly extends its half-life compared to native tuftsin.
Selank is approved in Russia as a pharmaceutical for the treatment of generalized anxiety disorder (GAD) and neurasthenia. The research interest outside Russia centers on its unusual dual action — it appears to modulate both neurological and immune pathways, which is uncommon among anxiolytic compounds.
How it works (proposed mechanisms)
GABA modulation
A 2008 study by Seredenin and Kozlovskaya published in the Bulletin of Experimental Biology and Medicinefound that Selank modulates GABA metabolism through enkephalinase inhibition, increasing endogenous GABA levels. Unlike benzodiazepines, which directly bind GABA-A receptors, Selank's indirect mechanism produces anxiolytic effects without the sedation or dependence risks observed in preclinical models.
Brain-derived neurotrophic factor
Preclinical research by Seredenin et al. (2010, Bulletin of Experimental Biology and Medicine) indicated that Selank increases BDNF expression in the hippocampus of rat models. BDNF is one of the most studied biomarkers in cognitive neuroscience — it's involved in neuroplasticity, learning, memory formation, and mood regulation.
Serotonin and dopamine modulation
Research by Kozlovskii and Danchev (2003, Bulletin of Experimental Biology and Medicine) demonstrated that Selank influences serotonin and dopamine metabolism in rat brain tissue, stabilizing the balance between these neurotransmitters. The effect on serotonin turnover was observed in the frontal cortex and hippocampus, regions associated with mood and anxiety processing.
Tuftsin-derived immune effects
As a tuftsin analog, Selank retains some of its parent peptide's immune-modulating properties. Research by Ershov et al. (2009, Bulletin of Experimental Biology and Medicine) found that Selank influences the expression of 84 immune-related genes in human blood cells, including cytokine and chemokine pathways. Its primary clinical interest is neurological, but the immune effects are an active research area.
Most mechanistic data comes from preclinical research and the Russian pharmaceutical approval process. Western peer-reviewed clinical data is limited.
What the research suggests
Selank has pharmaceutical approval in Russia, which means clinical data exists — though much of it is published in Russian-language journals with limited accessibility in Western databases.
Anxiolytic properties
The Russian clinical data supporting Selank's approval for GAD was reviewed by Seredenin and Kozlovskaya (2012, Eksperimental'naya i Klinicheskaya Farmakologiya). The reported anxiolytic effect was comparable to low-dose benzodiazepines in controlled settings, but without sedation, cognitive impairment, or the dependence profile. The absence of rebound anxiety after discontinuation was specifically noted. Western replication of these results is limited.
Cognitive performance
Research by Kozlovskii and Danchev (2002, 2003) published in the Bulletin of Experimental Biology and Medicine reported that Selank improved memory consolidation and learning performance in rat models, potentially through its effects on BDNF and monoamine pathways. Rats showed improved performance in passive avoidance and Morris water maze tests. Human cognitive data is early-stage and limited to Russian clinical reports.
Immune support
As a tuftsin derivative, Selank retains immunomodulatory properties. Ershov et al. (2009) demonstrated gene expression changes in 84 immune-related genes in human leukocytes after Selank exposure. The research suggests influence on innate immune responses, though this application is secondary to its primary neurological use.
Administration (research context)
In its approved pharmaceutical form in Russia, Selank is administered as a nasal spray (0.15% solution). This route provides direct access to the central nervous system via the olfactory and trigeminal nerve pathways, bypassing the blood-brain barrier more effectively than oral administration.
Some research has also studied subcutaneous injection. Nasal delivery is the more common route in both the approved product and research contexts.
This is research context, not prescribing guidance. PepScribe does not currently offer Selank and this information should not be interpreted as a dosing recommendation.
Side effects & safety considerations
Based on the available data from clinical research and pharmaceutical use in Russia.
Reported side effects
- •Fatigue or mild sedation (particularly at higher doses)
- •Nasal irritation (with intranasal administration)
- •Occasional headache
Safety profile notes
Russian pharmaceutical data, reviewed by Seredenin and Kozlovskaya (2012), reports a favorable safety profile with no reported dependence or withdrawal symptoms — a notable distinction from benzodiazepines and other traditional anxiolytics. Preclinical toxicology studies found no mutagenic or teratogenic effects. Western peer-reviewed safety data is limited, so this should be interpreted with that caveat.
Consult a healthcare provider before considering any peptide therapy. This information is educational and does not replace medical advice.
Legal status
Selank is on the FDA's Category 2 list in the United States. It cannot be legally compounded by US pharmacies as of April 2026.
It is approved as a pharmaceutical product in Russia for anxiety and neurasthenia. In the US, it has no FDA approval as a drug, and its Category 2 bulk substance classification prevents compounding.
Reclassification to Category 1 is expected as part of the broader HHS peptide review, but no formal action has been taken. Gray-market vendors sell products labeled as Selank, but these are unregulated and lack pharmaceutical-grade quality controls.
While Selank isn't available, these physician-prescribed options may support cognitive and cellular health
Cognitive function, neuroprotection, and cellular energy — through legally available, pharmacy-compounded therapies prescribed by a licensed clinician.
NAD+
Supports cellular energy production and cognitive function. NAD+ plays a direct role in brain energy metabolism and neuroprotective pathways. Physician-prescribed and delivered to your door.
Get started →Sermorelin
Growth hormone-releasing peptide. GH supports deep sleep, cognitive recovery, and overall brain health. Physician-prescribed and shipped to your door.
Get started →Get notified when Selank becomes available
Be the first to know when Selank becomes available through PepScribe. We'll email you when Selank becomes legally available through US compounding pharmacies — no spam, no selling your data.
We're building the clinical and pharmacy infrastructure now so we can offer Selank from day one of reclassification.
Deep dives on Selank
Research-backed articles covering specific topics in depth.